Presentation on theme: "Claudia P. Hochberg, MD, FACC"— Presentation transcript:
1 Claudia P. Hochberg, MD, FACC Acute Coronary Syndromes - Recognition, Risk Stratification, and ManagementClaudia P. Hochberg, MD, FACCAugust 12, 2013
2 Topics to Cover Identification of the patient with ACS Initiation of anti-thrombotic therapy and anti-ischemic therapyRisk stratification as it relates to the decision of early invasive vs. conservative strategySecondary prevention/risk factor modificationWe could talk about a number of topics; however, given time constraints, will focus on the most critical issues that relate to the role of the PCP in ACS: (1) initial evaluation (2) initiation of therapy (3) risk stratification (as it relates to invasive vs conservative approaches) and (4) secondary prevention/risk factor modificationControversial areas are highlighted in red
3 124 Class I recommendations 23 Class III recommendations
4 Acute Coronary Syndrome An ischemic myocardial event that is a direct consequence of atherosclerotic plaque activation and/or local thrombus formationMay be divided into that association with ST segment elevation and that associated with ST segment depressionSpectrum: UANSTEMISTEMI“Acute coronary syndrome” has evolved as a useful operational term to refer to any constellation of clinicalsymptoms that are compatible with acute myocardial ischemia (Fig. 1). It encompasses MI (ST-segment elevation and depression, Q wave and non-Q wave) and UA.
5 Acute Myocardial Infarction: Definition 1. Typical rise and fall of biochemical markers of myocardial necrosis (troponin or CK-MB) with at least one of the following:a) ischemic symptomsb) development of pathologic Q waves on EKGc) ischemic EKG changes (ST depression or elevation)d) coronary intervention2. Pathologic findings of an acute MI
6 Unstable Angina: Guideline Definition Three principal presentations:Rest angina >20 minutes in last weekNew onset angina in last 2 monthsIncreasing angina - increased frequency, duration, or severity
7 Hospital Admissions for ACS: Unstable Angina/NSTEMI vs STEMI Acute Coronary Syndrome2.3 Million Hospital AdmissionsACSUA/NSTEMISTEMIApproximately 2.3 million Americans will present to the emergency department with chest pain due to acute coronary syndrome.1 Of these patients, twice as many (1.43 million) will be admitted and diagnosed with unstable angina (UA) or non–ST-segment elevation myocardial infarction (NSTEMI) compared with 829,000 patients who will be diagnosed with ST- segment-elevation myocardial infarction (STEMI).1 According to the American Heart Association, 1.1 million new or recurrent coronary attacks (defined as MI or coronary heart disease) will occur this year.2 Of these cases, 650,000 will be first cases and 450,000 will be recurrent cases. Additionally, about 150,000 new cases of UA will be diagnosed.21.43 millionAdmissions per Year829,000Admissions per YearSodnick EJ, et al. National Center for Health Statistics
8 Mr JS 65 yo male with h/o HTN, hyperlipidemia Had 1st episode of chest pain (a “pressure” with radiation to his left shoulder) 2 weeks prior to admit, while shoveling snow. Over the 3 days prior to admit he had 4 episodes of chest pain, initially with mild exertion, and finally at rest. The pain resolved spontaneously in 3-4 minutes.Meds: atenolol, amlodipine, HCTZ, atorvastatin, aspirinBP: 136/95 HR: 92No vascular bruits, no murmur, +S4, no congestion65 yo AAM with h/o HTN, hyperlipidemia, presents with likely UA/ACS. notes first episode of chest pain 2 weeks ago while shoveling snow. Over the past 3 days has had 4 episodes of chest pain, occurring with mild exertion (1 episode at rest). Today had an episode after climbing stairs. In ER was hypertensive -> iv labetolol with improvement. Exam currently with HR in 60s, SBP 140. No vascular bruits. No congestion. Faint SEM at LLSB. ECG with diffuse Twave inversion in precordium (concordant with the major deflection of the QRS). Labs with troponin 0.1, creat 1.38, hct 42. CXR negative, head CT (for dizziness) negative for acute abnormality. Bedside echo with apical and anterior HK. Given stuttering pattern of chest pain with significant ECG changes, wall motion abnormality, and mild troponin leak, I would favor an aggessive/invasive approach. Currently he is chest pain free and ate lunch at ~ 12:30 pm. Thus would medically manage today and plan cath in am.How can we tell if this man is having an ACS?
9 Labs normal except troponin 0.15, CK: 370 Acute presentationBaselineLabs normal except troponin 0.15, CK: 370
10 Chest Pain History and Diagnosis of Acute Myocardial Infarction (AMI) This article concluded that the character of the CP cannot fully distinguish those patient who are having an ACS from those who are not. However, there are some characteristics that remain helpful.Swap, C. J. et al. JAMA 2005;294:
11 Likelihood that Signs and Symptoms Represent ACS Secondary to CAD HIGHLeft arm or chest pain typical of prior anginaHx of CAD or MICHFTransient MR murmurHypotensionNew ECG changes (ST deviation > 1mm; Twave inversion in many leads)Elevated biomarkers (troponin/CK-MB)IntermediateLeft arm or chest painAge > 70 yearsMaleDiabetesPVD,CVAQ waves on ECGST deviation mm, Twave inversion > 1 mmNormal biomarkersThe efficient diagnosis and optimal management of these patients must derive from information readily available at the time of the initial clinical presentation.When a patient presents with symptoms, how do we distinguish which patients are have ACS from those that are likely to have nonischemic symptomsCLASS I1. A rapid clinical determination of the likelihood risk of obstructive CAD (i.e., high, intermediate, or low) should be made in allpatients with chest discomfort or other symptoms suggestive of an ACS and considered in patient management. (Level of Evidence:C)Circulation. 2007;116:e148–e304.
12 Likelihood that Signs and Symptoms Represent ACS Secondary to CAD LowProbable ischemic symptom in absence of intermediate risk markersRecent cocaine usePain reproduced by palpationT wave inversion < 1 mmNormal ECGNormal biomarkersThe initial challenge in managing patients with ACS is to identify those patients likely to have ACS.Circulation. 2007;116:e148–e304.
13 Initial Anti-Ischemic Therapies (Class I) Bed Rest (~ 24 hours)OxygenNitratesMorphine SulfateBeta-blocker (within the 1st 24 hours in patients without contraindications)Non-dihydropyridine CCB (verapamil/dilt) in patients with contraindications to BBACE inhibitor for HTN, low LVEF or CHF or DMDiscontinue NSAIDsBed rest x 24 hrs (until r/in or r/out)Nitrates for anginal control, CHFBB: iv x 3 doses if BP and HR allow, then oraldose orallly q8hrs for 1st 24 hours, especially in patients without prior BBtransition to long acting med at d/cif LVEF<40%, consider carvedilol (slow titration and monitor BP)A. ANTI-ISCHEMIC AND ANALGESIC THERAPYCLASS I1. Bed/chair rest with continuous ECG monitoring is recommended forall UA/NSTEMI patients during the early hospital phase. (Level ofEvidence: C)2. Supplemental oxygen should be administered to patients withUA/NSTEMI with an arterial saturation less than 90%, respiratorydistress, or other high-risk features for hypoxemia. (Pulse oximetryis useful for continuous measurement of SaO2.) (Level ofEvidence: B)3. Patients with UA/NSTEMI with ongoing ischemic discomfort shouldreceive sublingual NTG (0. 4 mg) every 5 min for a total of 3 doses,after which assessment should be made about the need for intravenousNTG, if not contraindicated. (Level of Evidence: C)4. Intravenous NTG is indicated in the first 48 h after UA/NSTEMI fortreatment of persistent ischemia, heart failure (HF), or hypertension.The decision to administer intravenous NTG and the dose usedshould not preclude therapy with other proven mortality-reducinginterventions such as beta blockers or angiotensin-converting enzyme(ACE) inhibitors. (Level of Evidence: B)5. Oral beta-blocker therapy should be initiated within the first 24 h for patients who do not have 1 or more of the following: 1) signs of HF, 2) evidence of a low-output state, 3) increased risk* for cardiogenic shock, or 4) other relative contraindications to beta blockade (PR interval greater than s, second or third degree heart block, active asthma, or reactive airway disease). (Level of Evidence: B)Based on the COMMIT/CCS2 trial, the largest randomized trial of BB in MI, it seems reasonable to defer treatment with BB in patients who are hemodynamically compromised, in whom BB may be assoc with increased mortality.6. In UA/NSTEMI patients with continuing or frequently recurring ischemiaand in whom beta blockers are contraindicated, a nondihydropyridinecalcium channel blocker (e.g., verapamil or diltiazem)should be given as initial therapy in the absence of clinicallysignificant left ventricular (LV) dysfunction or other contraindications.(Level of Evidence: B)7. An ACE inhibitor should be administered orally within the first 24 hto UA/NSTEMI patients with pulmonary congestion or LV ejectionfraction (LVEF) less than or equal to 0.40, in the absence ofhypotension (systolic blood pressure less than 100 mm Hg or lessthan 30 mm Hg below baseline) or known contraindications to thatclass of medications. (Level of Evidence: A)8. An angiotensin receptor blocker should be administered to UA/NSTEMI patients who are intolerant of ACE inhibitors and haveeither clinical or radiological signs of HF or LVEF less than or equalto (Level of Evidence: A)9. Because of the increased risks of mortality, reinfarction, hypertension, CHF, and myocardial rupture associated with their use, nonsteroidal anti- inflammatory drugs (NSAIDs), except for ASA, whether nonselective or cyclooxygenase (COX)-2–selective agents, should be discontinued at the time a patient presents with UA/NSTEMI. (Level of Evidence: C)Circulation. 2007;116:e148–e304.
14 What Anti-Thrombotic Therapy Should be Used in the Initial Hours of Management of ACS?
15 The Vulnerable Plaque Plaque rupture Platelet adhesion Images from Falk E, et al. Circulation. 1998;92:Plaque rupturePlatelet adhesionPlatelet activationPlatelet aggregationThrombotic occlusionA cross-section of a coronary artery demonstrating the vulnerable plaque, with its large lipid core and thin fibrous cap
16 Characteristics of Unstable and Stable Plaque Lack of inflammatory cellsInflammatory cellsThin fibrous capThick fibrous capFew SMCsMore SMCsUnstable plaques are characterized by a large lipid core and thin fibrous cap. Inflammatory cells and activated macrophages are believed to be involved in destabilizing the plaque and the fibrous cap.Intact endotheliumEroded endotheliumActivated macrophagesFoam cellsAdapted with permission from Libby P. Circulation. 1995;91: Slide reproduced with permission from Cannon CP. Atherothrombosis slide compendium. Available at:
18 Thrombus Formation and ACS UANQMIQWMIPlaque Disruption/Fissure/ErosionThrombus FormationNon-ST-Segment Elevation Acute Coronary Syndrome (ACS)ST-Segment Elevation Acute Coronary Syndrome (ACS)OldTerminology:NewIt is now recognized that unstable angina (UA), non-Q-wave myocardial infarction (NQMI), and ST-segment elevation myocardial infarction (STE-MI) are all parts of the spectrum of clinical manifestations of acute coronary syndrome (ACS). The older terminology has now been replaced with terminology that divides ACS into non-ST-elevation ACS (NSTE-ACS) and ST-segment-elevation. All the slides in this teaching set deal with NSTE-ACS.
19 Pathogenesis of Acute Coronary Syndromes: The integral role of platelets PlaqueFissure or RupturePlateletAdhesionPlateletActivationPlateletAggregationPlatelets are recognized to play an integral role in acute coronary syndromes and arterial thrombosis. After plaque fissure or rupture, there is platelet adhesion and activation. This leads to platelet aggregation within the coronary artery, and ultimately partial or complete occlusion of the coronary artery.ThromboticOcclusion
20 Antiplatelet Therapy in ACS Act by inhibiting different platelet functions (aggregation, release of granule contents, platelet-mediated vascular constriction)Aspirin: blocks cyclooxygenase which mediates the first step in the biosynthesis of prostaglandins and thromboxanes from arachidonic acid P2Y12 receptor blockers:clopidogrel, ticlopidine, prasugrel, ticagrelor all block the binding of ADP to P2Y12R-->inhibits activation of the GP IIb/IIIa complex and platelet aggregationGP IIb/IIIa inhibitors:inhibit the final common pathway of platelet aggregation (cross-bridging of platelets by fibrinogen)20
21 Region of vascular injury CollagenvWF? Anti-vWF ? Anti-GpIbGpIbThrombinAspirinTSITXA2UF heparin LMWH Thrombin inhibitorsAA PGH TXA2TXA2 receptor antagonistADPFibrinogenEpiADPGPIIb/IIIathienopyridineThere are multiple mediators which can result in platelet activation, including ADP, epinephrine, collagen, arachidonic acid, and thrombin. Aspirin blocks activation of platelets by arachidonic acid. The thienopyridines (ticlopidine and clopidogrel) block ADP-mediated platelet activation. Antithrombin therapy (heparin, low-molecular-weight heparin, or direct thrombin inhibitors) block thrombin-mediated platelet activation. The glycoprotein IIb/IIIa inhibitors block platelet aggregation by inhibiting fibrin from binding to the GP IIb/IIIa receptorGpIIB/IIIA inhibitorsFibrinGPIIb/IIIaAwtry EH, Loscalzo J 2003
22 Aspirin The Antithrombotic Trialists' Collaboration Aspirin ( mg daily) in 200,000 patientsAntiplatelet therapy produced a significant 46% reduction in the combined end point of subsequent nonfatal myocardial infarction (MI), nonfatal stroke, or vascular death (8.0 vs 13.3%) in patients with unstable angina30 percent reduction in patients with acute myocardial infarction (10.4 vs 14.2 %)No significant difference in efficacy between lower and higher daily doses (75 to 325 versus 500 to 1500 mg)The addition of a second antiplatelet agent (eg, dipyridamole, ticlopidine, or intravenous glycoprotein IIb/IIIa inhibitor) significantly lowered the combined end pointTextAntithrombotic Trialists' Collaboration. BMJ 2002; 324:71.22
23 Treatment of Unstable Angina Results of a study from the Montreal Heart InstituteIn multiple studies aspirin significantly reduces risk of:- subsequent MI- cardiac death- overall mortality(>50% reduction)121086% Developing MI4Studies, including this one from the Montreal Heart Institute, demonstrated that treating patients with aspirin could reduce ischemic complications in patients with unstable angina.2placeboaspirinTheroux P, et al. N Engl J Med.1988;319:
24 AspirinClass Img should be given on day one and continued indefinitely (may be decreased to 81mg daily after the acute event if no PCI, or after PCI).Class IIb1. Other antiplatelet agents such as clopidogrel ( mg po loading dose, then 75 mg QD) or prasugrel may be substituted if true aspirin allergy is present.Circulation. 2007;116:e148–e304.
25 P2Y12 Receptor BlockersCURE trial: randomly assigned 12,562 patients who presented within 24 hours after the onset of a NSTEMI to aspirin alone (75 to 325 mg/day) or with clopidogrel (300 mg loading dose followed by 75 mg/day) for 9 to 12 monthsHigh risk patients :electrocardiogram (ECG) changeselevated cardiac enzymes60 % did not receive revascularizationPrimary endpoint: cardiovascular death, myocardial infarction, or strokeAt an average follow-up of nine months, combination therapy led to a significant reduction in the combined primary endpoint (9.3 vs 11.4%), largely due to fewer MIs (5.2 vs 6.7%)Clopidogrel increased the rate of major bleeding (3.7 vs 2.7 %) but not in life-threatening bleeding or hemorrhagic stroke25Yusuf S, et al. N Engl J Med. 2001;345:
26 CURE: Primary Composite End Point (CV Death/MI/Stroke) Placebo + Aspirin20%RRR1412P=.00009108% With EventClopidogrel + Aspirin64The CURE study demonstrated that in population treated predominantly with medical therapy alone (without early cardiac catheterization and revascularization), and without up-front GP IIb/IIIa therapy, the addition of clopidogrel (to aspirin and heparin) resulted in a 20% relative reduction in the composite ischemic endpoint. Approximately half of the benefit occurred over the first thirty days, and approximately half of the overall benefit occurred during the remaining duration of treatmentHowever, the trial also revealed that in patients going to CABG, the risk of bleeding was significantly increased.236912Follow-up (months)Yusuf S, et al. N Engl J Med. 2001;345:
27 CURE Bleeding Complications Major bleeding was increased in the CURE study in those patients treated with a combination of aspirin and clopidogrel when compared to those treated with aspirin and placeboData from Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:
28 ACC/AHA Recommendations - Antiplatelet Therapy for NSTE-ACS Class IClopidogrel if ASA-allergic or intolerantClopidogrel in addition to ASA if early invasive approach not planned (for 1–12 months)Clopidogrel in addition to ASA, if invasive approach is plannedClopidogrel should be withheld for 5-7 days if CABG plannedINCLUDE IN HANDOUT, NOT IN LECTUREThe ACC/AHA Guidelines Update for the Management of Patients with Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction make several recommendations regarding anti-platelet therapy in patients with NSTE-ACS. There are subtle differences with regard to GP IIb/IIIa therapy, depending upon whether on not the patient is to undergo early cardiac catheterization and PCI, and upon whether or not the patient has been treated with clopidogrel. The issue of whether to treat all patients with NSTE-ACS in the ER with clopidogrel and accept that some will have to have CABG delayed until the clopidogrel effects abate, or whether to wait until the coronary arteries are defined before starting clopidogrel, is subject to debate, although at present the ACC/AHA guidelines are as listed in the slide. Up-front GP IIb/IIIa therapy should be with either eptifibatide or tirofiban.Circulation. 2007;116:e148–e304.
29 Comparison of Heparin + ASA vs ASA AloneTherouxRISCCohen 1990ATACSHoldrightGurfinkelSummary Relative RiskIndividual studies and cumulative data strongly suggest the additional benefit of risk reduction (risk of MI) in patients with unstable angina when unfractionated heparin is added to treatment with aspirin.0.67 ( )0.1110Heparin + ASA 55/698=7.9%RR:Death/MIASA Alone 68/655=10.4%Oler A, et al. JAMA. 1996;276:
30 Anticoagulants Unfractionated Heparin (UFH) Most widely usedMost widely usedantithromboticantithromboticagentagentDisadvantages include:Disadvantages include:PoorPoorbioavailabilitybioavailabilityNo inhibition of clot-bound thrombinNo inhibition of clot-bound thrombinDependent onDependent onantithrombinantithrombinIII (ATIII) cofactorIII (ATIII) cofactorINCLUDE IN HANDOUT NOT IN LECTUREVariable effectsVariable effectsFrequent monitoring (Frequent monitoring (aPTTaPTT) to ensure therapeutic levels) to ensure therapeutic levelsReboundReboundischemiaischemiaafter discontinuationafter discontinuationRisk of heparin-inducedRisk of heparin-inducedthrombocytopeniathrombocytopenia(HIT)(HIT)
31 Anticoagulants Low-Molecular-Weight Heparin (LMWH) Fraction of standard (UFH) heparinFraction of standard (UFH) heparinAdvantages over UFH:Advantages over UFH:GreaterGreaterbioavailabilitybioavailabilityNo need to closely monitorNo need to closely monitorResistant to inhibition by activated plateletsResistant to inhibition by activated plateletsLower incidence of HITLower incidence of HITINCLUDE IN HANDOUT NOT IN LECTUREEnhanced anti-factorEnhanced anti-factorXaXaactivityactivityEffective subcutaneous administrationEffective subcutaneous administrationEnoxaparinEnoxaparin,,dalteparindalteparin,,reviparinreviparin,,nadroparinnadroparin,,fraxiparinfraxiparin, others, othersDiffer in anti-Differ in anti-XaXa/anti-/anti-IIaIIaratiosratios
32 Urgent Revascularization UFH vs LMWHESSENCETIMI 11B30%25%20%15%10%913Days After Randomization172155%2529Unfractionated HeparinEnoxaparin (Lovenox)Recurrent AnginaDeath, MI orP = 0.02Risk Reduction 16.2%Urgent RevascularizationDeath, MI orUnfractionated HeparinEnoxaparin (Lovenox)Days201612842610141.7%p = 0.03Relative Risk Reduction = 15%Cohen M, et al. N Engl J Med. 1997;337:Antman EM, et al. Circulation. 1999;100:
33 Guidelines for the Use of Enoxaparin in Patients with NSTE-ACS 1 mg/kg SQ q12 hours (actual body weight)An initial 30 mg IV dose can be consideredAdjust dosing if CrCl <30 cc/min1 mg/kg SQ q24 hoursDo not follow PTT; do not adjust based on PTTStop if platelets < by 50% or below 100,000/mm3If patient to undergo PCI:0-8 hours since last SQ dose: no additional antithrombin therapy8-12 hours since last SQ dose: 0.3 mg/kg IV during PCIGuidelines for the use of enoxaparin in patients with NSTE-ACS.
35 TIMI Risk Score For UA/NSTEMI 4.78.313.219.9220.127.116.11.614.92028.814.1103040500/123456/7D/MI/Urg Revasc(%)Number of Risk FactorsUFHENOXAntmanet alJAMA 284: 835, 2000•Age>65 y3 CAD Risk FactorsPriorStenosis> 50 %ST deviationAnginalevents<24 hASA in last 7 daysElevCardiac MarkersESSENCE and TIMI 11B: Rate of increase in composite events was less inpatients treated with enoxaparin than in patients treated with UFH
36 ACC/AHA Recommendations for Antithrombin Therapy in Patients with NSTE-ACS Class I:Anticoagulation should be added to antiplatelet therapy as soon as possible after recognition of ACSIf early invasive strategy: may use UFH (60-70 U/kg to max 5000 IV followed by infusion of U/kg/hr (initial max 1000 U/hr) titrated to aPTT times control), enoxaparin (1 mg/kg subcutaneously q12 hr)If conservative strategy: may use UFH, enoxaparin, or fondaparinuxClass IIaEnoxaparin or fondaparinux is preferable to UFH as an anticoagulant unless CABG is planned within 24 hoursFondaparinox is a synthetic heparin pentasaccharideThe ACC/AHA Guidelines Update for the Management of Patients with Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction make several recommendations regarding antithrombin therapy in patients with NSTE-ACS. The use of either unfractionated heparin (UFH) or a low molecular weight heparin (LMWH) is a class I recommendation. Based primarily on the ESSENCE and TIMI 11B studies, a class IIa recommendation was that enoxaparin was preferable to UFH. Whether this preferential recommendation changes as a result of the SYNERY study remains to be determined.CLASS IAnticoagulant therapy should be added to antiplatelet therapy inUA/NSTEMI patients as soon as possible after presentation.a. For patients in whom an invasive strategy is selected, regimens withestablished efficacy at a Level of Evidence: A include enoxaparin andUFH (Fig. 6; Box B1), and those with established efficacy at a Level ofEvidence: B include bivalirudin and fondaparinux (Fig. 7; Box B1).b. For patients in whom a conservative strategy is selected, regimensusing either enoxaparin* or UFH (Level of Evidence: A) or fondaparinux(Level of Evidence: B) have established efficacy. (Fig. 8; BoxC1)* See also Class IIa recommendation below.c. In patients in whom a conservative strategy is selected and whohave an increased risk of bleeding, fondaparinux is preferable.(Level of Evidence: B) (Fig. 7; Box C1)Circulation. 2007;116:e148–e304.
37 ACC/AHA Recommendations for Antithrombin Therapy in Patients with NSTE-ACS Class I:Anticoagulation should be added to antiplatelet therapy as soon as possible after recognition of ACSIf early invasive strategy: may use UFH (60-70 U/kg to max 5000 IV followed by infusion of U/kg/hr (initial max 1000 U/hr) titrated to aPTT times control), enoxaparin (1 mg/kg subcutaneously q12 hr), or direct thrombin inhibitors (bivalirudin or fondiparinux)If conservative strategy: may use UFH, enoxaparin, or fondaparinuxClass IIaEnoxaparin or fondaparinux is preferable to UFH as an anticoagulant unless CABG is planned within 24 hours** Unfractionated heparin preferred in patients with creatinine > 2.0 (Cr clearance <30) or weight >120 kgFondaparinox is a synthetic heparin pentasaccharideThe ACC/AHA Guidelines Update for the Management of Patients with Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction make several recommendations regarding antithrombin therapy in patients with NSTE-ACS. The use of either unfractionated heparin (UFH) or a low molecular weight heparin (LMWH) is a class I recommendation. Based primarily on the ESSENCE and TIMI 11B studies, a class IIa recommendation was that enoxaparin was preferable to UFH. Whether this preferential recommendation changes as a result of the SYNERY study remains to be determined.CLASS IAnticoagulant therapy should be added to antiplatelet therapy inUA/NSTEMI patients as soon as possible after presentation.a. For patients in whom an invasive strategy is selected, regimens withestablished efficacy at a Level of Evidence: A include enoxaparin andUFH (Fig. 6; Box B1), and those with established efficacy at a Level ofEvidence: B include bivalirudin and fondaparinux (Fig. 7; Box B1).b. For patients in whom a conservative strategy is selected, regimensusing either enoxaparin* or UFH (Level of Evidence: A) or fondaparinux(Level of Evidence: B) have established efficacy. (Fig. 8; BoxC1)* See also Class IIa recommendation below.c. In patients in whom a conservative strategy is selected and whohave an increased risk of bleeding, fondaparinux is preferable.(Level of Evidence: B) (Fig. 7; Box C1)Circulation. 2007;116:e148–e304.
38 IIb/IIIa Inhibitors in ACS PURSUITPRISMPRISM PLUSPARAGON BPARAGON ATherouxCOMBINED 1998 (n = 23,967)0.88 ( )0.250.501.02.04.0Odds Ratio for 30-day Death or MI Relative to Control
39 ACC/AHA Recommendations - Antiplatelet Therapy for NSTE-ACS Class IClopidogrel OR GP IIb/IIIa inhibitor, in addition to ASA, if invasive approach is plannedClass IIaGP IIb/IIIa inhibitor in patients with high-risk features if invasive strategy not plannedGP IIb/IIIa inhibitor in patients receiving clopidogrel if cardiac cath and PCI plannedClass IIbGP IIb/IIIa inhibitor in patients without high-risk features and PCI not plannedINCLUDE IN HANDOUT, NOT IN LECTUREThe ACC/AHA Guidelines Update for the Management of Patients with Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction make several recommendations regarding anti-platelet therapy in patients with NSTE-ACS. There are subtle differences with regard to GP IIb/IIIa therapy, depending upon whether on not the patient is to undergo early cardiac catheterization and PCI, and upon whether or not the patient has been treated with clopidogrel. The issue of whether to treat all patients with NSTE-ACS in the ER with clopidogrel and accept that some will have to have CABG delayed until the clopidogrel effects abate, or whether to wait until the coronary arteries are defined before starting clopidogrel, is subject to debate, although at present the ACC/AHA guidelines are as listed in the slide. Up-front GP IIb/IIIa therapy should be with either eptifibatide or tirofiban.Available at:
40 GP IIb/IIIa Dosing and Administration for Up-Front Therapy in Patients with NSTE-ACS Integrilin: 180 mcg/kg bolus (over 1-2 min), then 2 mcg/kg/min continuous infusionAggrastat: Initial 0.4 mcg/kg/min for 30 min, then continuous infusion at 0.1 mcg/kg/minAlways also treat with ASA and some form of heparin (UFH or LMWH)Patients most commonly treated 2-4 daysFollow platelet count qD and D/C for significant fallAdjust doses for renal insufficiency:Integrilin: For creatinine 2-4 mg/dL, decrease infusion to 1 mcg/kg/min; avoid if creatinine >4 mg/dLAggrastat: For CrCl < 30 mL/min, cut all doses in 1/2INCLUDE IN HANDOUT, NOT IN LECTUREDosing and administration guidelines for the two GP IIb/IIIa inhibitors approved for “up-front” therapy in patients with NSTE-ACS.
41 Contraindications to GP IIb/IIIa Rx Active or recent bleeding (4-6 weeks)Severe hypertension (SBP > mm Hg; DBP >110 mm Hg)Any hemorrhagic CVA (+/- intracranial neoplasm, AVM, or aneurysm)Any CVA within 30 days–2 yearsMajor surgery or trauma within 4-6 weeksThrombocytopenia ( <100,000/mm3 )Bleeding diathesis/warfarin with elevated INRINCLUDE IN HANDOUT, NOT IN LECTUREThe specific contraindications for each of the three glycoprotein (GP) IIb/IIIa inhibitors varies somewhat, but can be generally summarized in the above slide.
42 IIb/IIIa Inhibitors in ACS PURSUITPRISMPRISM PLUSPARAGON BPARAGON ATherouxCOMBINED 1998 (n = 23,967)0.88 ( )EARLY ACSACUITY TimingEARLY ACS + ACUITY0.92 ( )EARLY ACSBackground Glycoprotein IIb/IIIa inhibitors are indicated in patients with acute coronary syndromes who are undergoing an invasive procedure. The optimal timing of the initiation of such therapy is unknown.Methods We compared a strategy of early, routine administration of eptifibatide with delayed, provisional administration in 9492 patients who had acute coronary syndromes without ST- segment elevation and who were assigned to an invasive strategy. Patients were randomly assigned to receive either early eptifibatide (two boluses, each containing 180 µg per kilogram of body weight, administered 10 minutes apart, and a standard infusion 12 hours before angiography) or a matching placebo infusion with provisional use of eptifibatide after angiography (delayed eptifibatide). The primary efficacy end point was a composite of death, myocardial infarction, recurrent ischemia requiring urgent revascularization, or the occurrence of a thrombotic complication during percutaneous coronary intervention that required bolus therapy opposite to the initial study-group assignment ("thrombotic bailout") at 96 hours. The key secondary end point was a composite of death or myocardial infarction within the first 30 days. Key safety end points were bleeding and the need for transfusion within the first 120 hours after randomization.Results The primary end point occurred in 9.3% of patients in the early-eptifibatide group and in 10.0% in the delayed-eptifibatide group (odds ratio, 0.92; 95% confidence interval [CI], 0.80 to 1.06; P=0.23). At 30 days, the rate of death or myocardial infarction was 11.2% in the early-eptifibatide group, as compared with 12.3% in the delayed-eptifibatide group (odds ratio, 0.89; 95% CI, 0.79 to 1.01; P=0.08). Patients in the early-eptifibatide group had significantly higher rates of bleeding and red-cell transfusion. There was no significant difference between the two groups in rates of severe bleeding or nonhemorrhagic serious adverse events.Conclusions In patients who had acute coronary syndromes without ST-segment elevation, the use of eptifibatide 12 hours or more before angiography was not superior to the provisional use of eptifibatide after angiography. The early use of eptifibatide was associated with an increased risk of non–life-threatening bleeding and need for transfusion. (ClinicalTrials.gov number, NCT [ClinicalTrials.gov] .)COMBINED 2009 (n = 42,666)0.89 ( )0.250.501.02.04.0Odds Ratio for 30-day Death or MI Relative to Control
43 Early ACS - Conclusions Among high-risk NSTE ACS patients, a strategy of routine, early eptifibatide compared with delayed, provisional eptifibatide at PCI did not significantly reduce the primary composite of death, MI; resulted in a trend toward reduction in death or MI at 30 days, but no difference in 30-day mortality; resulted in higher rates of non-life-threatening bleeding and transfusionsThe results of EARLY ACS do not support a strategy of routine early eptifibatide use in high-risk NSTE ACS patients managed with an invasive strategyNEJM on line March 30, 2009
44 How Best to Risk Stratify Patients with ACS? Because patients with ischemic discomfort at rest as a group are heterogeneous in terms of risk of cardiac death and nonfatal ischemic events, an assessment of the prognosis guides the initial evaluation and treatment. An estimation of risk is useful in 1) selection of the site of care (coronary care unit, monitored step-down unit, or outpatient setting) and 2) selection of therapy, including platelet glycoprotein (GP) IIb/IIIa inhibitors (see Section 3.2) and invasive management strategy (see Section 3.3).
45 Risk StratificationBased on validated risk prediction models that include the most important predictors of outcomesCertain patients that are such high risk that they need not be risk stratified:cardiogenic shockovert CHF or LV dysfunctionRest angina despite max medical therapyHemodynamic instability, mechanical complicationsUnstable ventricular arrythmias43
46 TIMI Risk Score for UA/NSTEMI Age >65 years3 or more CAD risk factorsHTN, DM, Hyperlipidemia, smoking, + family hxPrior CAD (cath stenosis>50%)ASA in last 7 days2 or more anginal events in last 24 hoursST deviation on admission ECGElevated cardiac markers (troponin/CK-MB)Our patient had a TIMI score of 5 (>65 yrs, asa, 2+ episodes, ST abn, + trop) – point out risk on next next slideAntman EM, et al. JAMA ;284:
47 14 day Death, MI, or Urgent Revascularization (%) The TIMI Risk Score and Incidence of Adverse Ischemic Events in Patients with NSTE-ACS5040.9403026.214 day Death, MI, or Urgent Revascularization (%)19.92013.28.3104.7The greater the number of TIMI Risk Score criteria, the greater the risk of adverse cardiac event.Our patient had a TIMI score of 5 (>65 yrs, asa, 2+ episodes, ST abn, + trop) – point out riskThe curves for individual risk are similar:Rates of all-cause mortality, myocardial infarction (MI), urgent revascularization, and all-cause mortality or nonfatal MI through 14 days after randomization were calculated for the entire population in the Thrombolysis in Myocardial Infarction (TIMI) 11B trial based on the TIMI risk score. There was a progressive, significant increase in the rate of events for each end point as the TIMI risk score increased (P<.001 by 2 for trend for all). C statistics for the 4 end points shown were 0.74 (all-cause mortality), (MI), 0.68 (urgent revascularization), and 0.63 (all-cause mortality/MI), respectively.0/123456/7# of Risk FactorsAntman EM, et al. JAMA ;284:Download at:
48 TIMI Risk Score for UA/NSTEMI Higher TIMI risk scores correlated with more severe angiographic diseasePRISM-PLUS:Increasing TIMI risk scores from 0-2 (low risk) to 5-7 (high risk) were associated with increases in the frequency of high-risk angiographic findings:>70 % culprit stenosis (from 58 to 81%)multivessel disease (43 to 80%)visible thrombus (30 to 41%)left main diseaseThe TIMI risk score can also identify patients most likely to benefit from particular therapies:In TACTICS-TIMI 18, only patients with score ≥3 benefited from early invasive strategyThe degree of troponin elevation and magnitude of ST segment deviation were independent predictors of an adverse outcome and of benefit from an early invasive strategyIn TIMI 11B and ESSENCE, enoxaparin was associated with better 14-day and six- week post-discharge outcomes compared to UFH; these benefits were primarily seen in high-risk patients with risk scores ≥4 and ≥5, respectivelyOur patient had a TIMI score of 5 (>65 yrs, asa, 2+ episodes, ST abn, + trop) – point out risk on next next slide
49 GRACE Risk CalculatorEstimates the risk of in-hospital and six-month mortality among all patients with an ACSThis end point is different from the composite end point in the TIMI risk score of all-cause mortality, new or recurrent MI, or severe recurrent ischemia requiring revascularizationWhile the GRACE prediction model is well validated and its use is recommended by multiple guideline organizations, its complexity makes it somewhat difficult to use in some clinical settings47
50 GRACE Risk Calculator – 6 month mortality after ACS Eagle et al. JAMA 2004;291:2727–33.
51 GRACE Risk Calculator – 6 month mortality after ACS 55151411311232%If you make the patient 80 with a h/o CHF, the risk increases significantly4%Eagle et al. JAMA 2004;291:2727–33.Download at:
52 Prognostic Value of Troponin T or I in ACS: A Meta-Analysis 18.104.22.1680.8510152025DeathDeath/MI%RR 3.9 ( )RR 3.8 ( )Neg Pos (Trop I + T)Troponin is an extremely powerful risk-stratifier. In one meta-analysis, the relative risks of death or of the combined endpoint of death+MI were 3.9 and 3.8, respectively, in patients who presented with NSTE-ACSHeidenreich PA, et al. JACC. 2001;38:
54 B-type Natriuretic Peptide (BNP) and Mortality in ACS Patients 10Quartile 4 (n=630)P<.001>138 pg/ml86Quartile 3 (n=632)Mortality (%)4Quartile 2 (n=632)Other risk stratifiers for patients who present with NSTE-ACS include the level of B-type natriuretic peptide (BNP)Figure 1. Kaplan–Meier Curves Showing the Cumulative Incidence of Death at 10 Months, According to the Quartile of B-Type Natriuretic Peptide Level at Enrollment.The range of B-type natriuretic peptide levels was as follows: 5.0 to 43.6 pg per milliliter (quartile 1), 43.7 to 81.2 pg per milliliter (quartile 2), 81.3 to pg per milliliter (quartile 3), and to pg per milliliter (quartile 4). P<0.001 for the trend among the quartiles.Background Brain (B-type) natriuretic peptide is a neurohormone synthesized predominantly in ventricular myocardium. Although the circulating level of this neurohormone has been shown to provide independent prognostic information in patients with transmural myocardial infarction, few data are available for patients with acute coronary syndromes in the absence of ST-segment elevation.Methods We measured B-type natriuretic peptide in plasma specimens obtained a mean (±SD) of 40±20 hours after the onset of ischemic symptoms in 2525 patients from the Orbofiban in Patients with Unstable Coronary Syndromes–Thrombolysis in Myocardial Infarction 16 study.Results The base-line level of B-type natriuretic peptide was correlated with the risk of death, heart failure, and myocardial infarction at 30 days and 10 months. The unadjusted rate of death increased in a stepwise fashion among patients in increasing quartiles of base-line B-type natriuretic peptide levels (P<0.001). This association remained significant in subgroups of patients who had myocardial infarction with ST-segment elevation (P=0.02), patients who had myocardial infarction without ST-segment elevation (P<0.001), and patients who had unstable angina (P<0.001). After adjustment for independent predictors of the long-term risk of death, the odds ratios for death at 10 months in the second, third, and fourth quartiles of B-type natriuretic peptide were 3.8 (95 percent confidence interval, 1.1 to 13.3), 4.0 (95 percent confidence interval, 1.2 to 13.7), and 5.8 (95 percent confidence interval, 1.7 to 19.7). The level of B-type natriuretic peptide was also associated with the risk of new or recurrent myocardial infarction (P=0.01) and new or worsening heart failure (P<0.001) at 10 months.Conclusions A single measurement of B-type natriuretic peptide, obtained in the first few days after the onset of ischemic symptoms, provides predictive information for use in risk stratification across the spectrum of acute coronary syndromes. Cardiac neurohormonal activation may be a unifying feature among patients at high risk for death after acute coronary syndromes2Quartile 1 (n=631)50100150200250300Days After RandomizationLemos JA,, et al. N Engl J Med. 2001;345:
55 Predictive Value of hs-CRP for Mortality from ACS in FRISC Substudy CRP >10mg/l (n=309)20CRP 2-10mg/l (n=294)Cumulative Probabilityof Death (%)10CRP <2mg/l (n=314)hs-CRP level has been shown to help to long-term risk-stratify patients with NSTE-ACS, with levels > 10 mg/l associated with a notable increase in the risk of long-term deathBackground In patients with unstable coronary artery disease, there is a relation between the short-term risk of death and blood levels of troponin T (a marker of myocardial damage) and C-reactive protein and fibrinogen (markers of inflammation). Using information obtained during an extension of the follow-up period in the Fragmin during Instability in Coronary Artery Disease trial, we evaluated the usefulness of troponin T, C-reactive protein, and fibrinogen levels and other indicators of risk as predictors of the long- term risk of death from cardiac causes.Methods Levels of C-reactive protein and fibrinogen at enrollment and the maximal level of troponin T during the first 24 hours after enrollment were analyzed in 917 patients included in a clinical trial of low-molecular-weight heparin in unstable coronary artery disease. The patients were followed for a mean of 37.0 months (range, 1.6 to 50.6).Results During follow-up, 1.2 percent of the 173 patients with maximal blood troponin T levels of less than 0.06 µg per liter died of cardiac causes, as compared with 8.7 percent of the 367 patients with levels of 0.06 to 0.59 µg per liter and 15.4 percent of the 377 patients with levels of at least 0.60 µg per liter (P= and P=0.001, respectively). The rates of death from cardiac causes were 5.7 percent among the 314 patients with blood C- reactive protein levels of less than 2 mg per liter, 7.8 percent among the 294 with levels of 2 to 10 mg per liter, and 16.5 percent among the 309 with levels of more than 10 mg per liter (P= 0.29 and P=0.001, respectively). The rates of death from cardiac causes were 5.4 percent among the 314 patients with blood fibrinogen levels of less than 3.4 g per liter, 12.0 percent among the 300 with levels of 3.4 to 3.9 g per liter, and 12.9 percent among the 303 with levels of at least 4.0 g per liter (P=0.004 and P=0.69, respectively). In a multivariate analysis, levels of troponin T and C-reactive protein were independent predictors of the risk of death from cardiac causes.Conclusions In unstable coronary artery disease, elevated levels of troponin T and C-reactive protein are strongly related to the long-term risk of death from cardiac causes. These markers are independent risk factors, and their effects are additive with respect to each other and other clinical indicators of risk.612182430364248MonthsLindahl B, et al.. N Engl J Med. 2000;343:
57 Invasive vs Conservative Strategy for UA/NSTEMI ISAR- COOL2003RITA-3VANQWISHVINOMATETRUCSTIMI IIIBTACTICS- TIMI 18FRISC IIConservativeNumerous studies involving over 7,000 patients have now consistently demonstrated that a strategy of early cardiac catheterization and revascularization in appropriately selected patients with NSTE-ACS leads to fewer adverse cardiac events than an initial strategy of medical therapy alone.InvasiveUA indicates unstable angina, NSTEMI, non–ST-segment myocardial infarction; ISAR, Intracoronary Stenting and Antithrombic Regimen Trial; RITA, Randomized Intervention Treatment of Angina; VANQWISH, Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital study; MATE, Medicine vs Angioplasty for Thrombolytic Exclusions trial; TACTICS-TIMI18, Treat Angina with Aggrastat® and Determine Cost of Therapy with Invasive or Conservative Strategy; and FRISC, Fragmin during InStability in Coronary artery disease.Slide reproduced with permission from Cannon CP. Atherothrombosis slide compendium. Available at:
58 TACTICS TIMI 18 20% 19.4% Initial Medical Rx 16% 15.9% 12% Patients (%)20%19.4%Initial Medical Rx16%15.9%12%Early Cath + PTCA8%4%The primary results from the TACTICS-TIMI 18 study demonstrated that the strategy of early cardiac catheterization and revascularization resulted in a statistically significantly lower incidence of adverse ischemic events at 6 months than a strategy of initial medical therapy.561234MonthsCumulative Incidence of the Primary Endpoint of Death, Nonfatal MI, rehospitalization for an ACS within 6 monthsCannon CP, et al. N Engl J Med. 2001;344:
59 TACTICS Trial Results Based on Troponin Initial Medical RxEarly Cath + PTCAP<0.00125%20%P=NS15%10%In TACTICS TIMI-18, patients with positive troponins experienced dramatically lower major ischemic events when treated with a strategy of early cardiac catheterization and revascularization5%NegativeTroponinPositiveTroponinCannon CP, et al. N Engl J Med. 2001;344:
60 Benefit of Invasive Strategy by Troponin and ST Changes Death, MI, or Rehospitalization for ACS at 6 MonthsConservativeP<.001P<.001Invasive3030P=NS25.0*P=NS24.5*2525202016.016.616.4*15.3*15.1CV Events (%)151512.41010Subgroup analysis from the TACTICS-TIMI 18 Study demonstrated that a strategy of early cardiac catheterization and revascularization reduced ischemic complications in patients with positive troponin T levels and in those with ischemic ST segment abnormalities. There was no significant difference in outcome in patients who lacked these risk markers.55TnT –TnT +No ST changeST changeMorrow DA, et al. JAMA. 2001;286: and Cannon CP, et al. N Engl J Med. 2001;344:
61 The Primary Composite Ischemic End Point in RITA-3 The RITA-3 trial also randomized patients with NSTE-ACS to either a strategy of early cardiac catheterization and revascularization, or to initial medical therapy. Those randomized to early intervention experienced a lower incidence of death, myocardial infarction, or recurrent unstable angina.Fox KA, Poole-Wilson PA, Henderson RA, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Lancet. 2002;360:
62 Meta-Analysis of Trials of Early Cardiac Cath and Revascularization Versus Initial Medical Therapy Alone in Patients with NSTE-ACSIndividual trials and metaanalysis of trials comparing strategies of early cardiac catheterization and revascularization with initial medical therapy alone in patients with NSTE-ACS.Fox KA, Poole-Wilson PA, Henderson RA, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Lancet. 2002;360:
63 TACTICS-TIMI18: Rates of Death, Nonfatal MI, or Rehospitalization for an ACS at Six Months, According to Base-Line CharacteristicsFigure 2. Rates of the Primary End Point of Death, Nonfatal Myocardial Infarction, or Rehospitalization for an Acute Coronary Syndrome at Six Months, According to Base-Line Characteristics. Odds ratios and 95 percent confidence intervals were determined by logistic-regression analysis. P values for the interaction were significant only for prior aspirin use (P=0.02) and ST-segment changes (P=0.006). For the analysis of the TIMI risk score, which assesses the risk of death and ischemic events in patients with unstable angina and myocardial infarction without ST-segment elevation, the upper bound of the confidence interval for a score of 3 to 4 was (P=0.048; P for the interaction among the three risk groups=0.15). Troponin T was measured at base line in a total of 1826 patients. MI denotes myocardial infarction.Cannon C et al. N Engl J Med 2001;344:
64 Early Invasive Therapy: Class I Recommendations Recurrent angina despite rx*Elevated cardiac markers*New ST-segment depression*Positive stress test*Symptoms of ischemic CHF, rales, MREF < 40%Sustained VTHypotension/hemodynamic instabilityPCI within 6 mos, prior CABGHigh risk score (TIMI, GRACE)In the absence of any of the above high-risk indicators, either an early conservative or an early invasive strategy is appropriateAn important recent advance in the management of NSTEASC has been the recognition that high risk patients benefit from early (before discharge) invasive investigation and coronary revascularisation compared with a more conservative, "ischaemia guided" strategy, whereby coronary arteriography and revascularisation are reserved for patients with ischaemia refractory to drug therapy or with evidence of inducible ischaemia on early non-invasive testing. Five prospective randomised studies have investigated this issue. The earliest, the TIMI IIIb trial, showed no difference between strategies in terms of rates of myocardial infarction and mortality.66 Hospital readmission was significantly reduced by the invasive approach. The veterans affairs non-Q-wave infarction strategies in hospital (VANQWISH) investigators reported an increased risk of death or non-fatal myocardial infarction with an early invasive strategy.67 This may be explained by the unusually high 30 day mortality rate after CABG in this study (12%).Both the TIMI IIIB and VANQWISH trials were conducted before the routine use of stents and GPIIb/IIIa inhibitors during percutaneous coronary intervention. As such, the results have to be interpreted with caution in the current day. Three subsequent studies have all shown superiority of early, "modern" invasive management. The fragmin and fast revascularisation during instability in coronary artery disease (FRISC) II study showed a significant reduction in all cause mortality and myocardial infarction at one year follow up, attributable to an invasive strategy.68 The TACTICS-TIMI 18 investigators randomised 2220 patients to early coronary arteriography followed by revascularisation as appropriate or a more conservative strategy in which catheterisation was only performed for recurrent ischaemia or positive stress testing.7 All patients received tirofiban for 48 hours before randomisation and cardiac catheterisation was carried out comparatively early (at a mean interval of 22 hours after randomisation) compared with the FRISC II study (mean interval six days). Again a benefit in favour of the invasive strategy was found with an absolute risk reduction of 3.5% in the rate of the primary end point (death, non-fatal myocardial infarction, or rehospitalisation for ACS). Of note, this benefit was restricted to high risk patients—that is, those with TIMI risk score 3, raised troponins, or ST segment deviation. Most recently, Fox et al published the results of the randomised intervention trial of unstable angina (RITA) 3 study.69 All 1810 patients studied were treated with subcutaneous enoxaparin and in the invasive arm, cardiac catheterisation took place at a mean of two days after enrolment. A primary end point of death, (re)infarction, or refractory angina at four months was prespecified and was observed in 9.6% of patients in the invasive arm compared with 14.5% of those in the conservative arm (p = 0.001).The remarkably consistent results observed by the FRISC II, TACTICS-TIMI 18, and RITA 3 investigators form a large, concrete evidence base on which it is recommended that in-patient coronary arteriography and revascularisation should be made available to all high risk NSTEACS patients. Low risk patients can be safely managed with an initial conservative approach with cardiac catheterisation reserved for those who develop recurrent ischaemia or who subsequently have a positive stress test.Selection for Coronary AngiographyIn contrast to the noninvasive tests, coronary angiography provides detailed structural information to allow an assessment of prognosis and to provide direction for appropriate management. When combined with LV angiography, it also allows an assessment of global and regional LV function. Indications for coronary angiography are interwoven with indications for possible therapeutic plans, such as PCI or CABG.Coronary angiography is usually indicated in patients with UA/NSTEMI who either have recurrent symptoms or ischemia despite adequate medical therapy or are at high risk as categorized by clinical findings (HF, serious ventricular arrhythmias) or noninvasive test findings (significant LV dysfunction: ejection fraction less than 0.35, large anterior or multiple perfusion defects; Tables 19, 20, and 21), as discussed in Section Patients with UA/NSTEMI who have had previous PCI or CABG also should generally be considered for early coronary angiography, unless prior coronary angiography data indicate that no further revascularization is likely to be possible. The placement of an IABP may allow coronaryangiography and revascularization in those with hemodynamic instability (see Section ). Patients with suspected Prinzmetal’s variant angina also are candidates for coronary angiography (see Section 6.7).In all cases, the general indications for coronary angiography and revascularization are tempered by individual patient characteristics and preferences. Patient and physician judgments regarding risks and benefits are particularly important for patients who might not be candidates forcoronary revascularization, such as very frail older adults and those with serious comorbid conditions (i.e., severe hepatic, pulmonary, or renal failure; active or inoperable cancer).Circulation. 2007;116:e148–e304.
65 Patient Up Date Treated with aspirin, clopidogrel, heparin Beta-blocker titrated to resting HR ~ bpmHigh dose statin givenCardiac catheterization performed.
68 Secondary Prevention - Risk Factor Modification Smoking CessationAchieve optimal weightIncrease physical activity level, cardiac rehabAHA dietHTN control to BP <130/85 mm HgStatin with goal LDL< 70Tight glycemic control in diabetics** Consider referral to cardiac rehab programCirculation. 2007;116:e148–e304.
69 Long-Term Medical Therapy: Class I Indications Aspirin 81 mg/dayClopidogrel 75 mg QD when ASA intolerantCombination ASA and clopidogrel/ticagrelor/prasugrel for 12 months after UA/NSTEMI/STEMI, 1 month BMS and 12 months DESBeta-blockerLipid-lowering and diet (if LDL>100)ACE Inhibitor if CHF, LV EF < 40%, HTN, DMNTG prn with clear instructions on useCirculation. 2007;116:e148–e304.
70 Guideline Compliance and Outcomes Figure 2. Link between American College of Cardiology/American Heart Association guideline adherence (hospital composite quality quartiles) and in-hospital mortality. Every 10% increase in guideline adherence was associated with a 10% reduction in in-hospital mortality (adapted from Peterson et al. ). *Adjusted for age, gender, body mass index, race, insurance status, family history of coronary disease, hypertension, diabetes, smoking, hypercholesterolemia, prior myocardial infarction/percutaneous coronary intervention/coronary bypass surgery/congestive heart failure/stroke, renal insufficiency, blood pressure, heart rate, ST-segment shift, and positive cardiac biomarkers.Tricoci P Et al. Am J Cardiol 2006;98:S30-S35.
71 SummaryThrombosis is central in the pathophysiology of ACS and mandates antithrombotic and antiplatelet therapyAll patients with ACS should be treated with aspirin and heparin.Consider treatment with Clopidogrel in patients who will be treated conservatively or those likely to undergo PCIUse of the TIMI risk score helps identify those patients that benefit from invasive therapiesImproved adherence to guidelines results in improved outcomes
72 Recommended Strategy in ACS: Boston Medical Center Guidelines CoronaryAngiographyPCI/CABGUA/ NSTEMIHigh RiskElevated TroponinRecurrent IschemiaDynamic EKG changesTIMI score > 3AspirinNitratesBeta-blockersUFH/LMWH? ClopidogrelLow RiskNormal Troponin onadmission and at 12 hTIMI score <2Stress TestPre-dc